FDA’s Concerns With Unapproved GLP-1 Drugs Used For Weight Loss From Harlem To Hawaii
The #1 source in the world for all things Harlem.
FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 (glucagon-like peptide-1 (GLP-1) receptor agonists) drugs, including semaglutide and tirzepatide, as an option for weight loss. This can be risky for patients, as unapproved versions do not undergo FDA’s review for safety, effectiveness and quality before they are…
The post FDA’s Concerns With Unapproved GLP-1 Drugs Used For Weight Loss From Harlem To Hawaii appeared first on Harlem World Magazine.